1
Improper Prescribing Practices: An Ethical Dilemma
Student’s Name
Institutional Affiliation
Professor’s Name
Course
Date
2
Improper Prescribing Practices: An Ethical Dilemma
As the director of pharmacy at a large regional medical center, I have an ethical and legal
responsibility to ensure that physician prescribing practices at our hospital meet accepted
standards of care. An issue has been brought to my attention regarding Dr. Smith, an oncologist
at our hospital, that causes me concern. As a Christian leader, I aim to address this complex
situation with wisdom, discernment, and compassion while seeking truth and justice. Scripture
compels us to make just decisions but also to season justice with grace. Our calling is to nurture
right living in a spirit of generosity, not merely enforce rigid rules. This challenging
circumstance provides an opportunity to model Christ-centered leadership by uncovering truth
and allowing for redemption where possible. I will investigate the issues thoroughly and initiate
open and honest dialogue with Dr. Smith in a spirit of patience and kindness. My goal is the
restoration of trust and reconciliation where feasible.
The Standards of Care
Prescribing any medication for purposes other than its FDA-approved indications is
considered “off-label” use. This practice is legal and common in some circumstances. However,
standards of care dictate that off-label prescribing should have sound scientific evidence
supporting its efficacy and safety for the proposed indication (Lee et al., 2023). Prescribing nonapproved medicines without reliable data is risky and raises ethical concerns. Additionally, some
institutions require oversight committees to approve off-label use on a case-by-case basis (Bell &
Richards, 2021). It does not appear that Dr. Smith’s unconventional cancer treatments are
evidence-based or have oversight committee approval. These deviations from standard oncology
practice put patients at risk with little potential benefit.
Informed Consent
3
Patients have a right to understand and consent to the treatments proposed by their
physicians. This requires an explanation of the treatment plan, disclosure of potential risks and
benefits, and discussion of alternatives (Van Norman, 2023). Cancer patients working with Dr.
Smith may not be receiving adequate informed consent regarding the experimental nature of the
treatments he offers. Desperate patients often grasp at straws when given a poor prognosis,
making full consent even more critical in oncology care. While patient autonomy should be
respected, physicians like Dr. Smith have an ethical duty to provide clear information regarding
the experimental treatments they recommend so that patients can make well-informed decisions.
Insurance, Reimbursement, and Legal Concerns
Prescribing non-approved medicines for unproven off-label indications also raises legal
and financial issues for our hospital. Government and private insurance companies expect
medical care to meet accepted quality standards to qualify for reimbursement (Van Norman,
2023). Payers may refuse coverage if they deem interventions as “experimental” or not medically
necessary by their criteria. This could result in the denial of reimbursement and uncovered costs
for the hospital. Additionally, fraudulent billing concerns may arise if coding does not accurately
reflect the experimental nature of Dr. Smith’s treatments. These practices undermine our
organization’s fiscal stewardship responsibilities. They could also motivate payers to launch
audits and investigations to recoup potentially inappropriate payments.
Hospital Reputation and Public Interests
As a director invested in the success of this organization, I share concerns about damage
to our hospital’s reputation if questionable practices by physicians are discovered. There are also
risks to public welfare interests, given Dr. Smith’s regional influence. Desperate patients travel
long distances to receive Dr. Smith’s promised cancer cures. Individuals may opt for his
4
treatments rather than proven standard of care at other facilities due to his renown. There is
potential harm if patients lose opportunities for evidence-based interventions that could extend
life or improve quality of life. Failure to address this physician’s practices reflects poorly on our
oversight of care quality and commitment to public service. We have a duty to protect patient
safety and welfare that supersedes a single provider’s interests or privileges.
Conflict of Interest Concerns
The fact that Dr. Smith owns a private clinic creates additional ethical dilemmas. His
request to obtain old hospital equipment for use in his separate facility raises conflict of interest
questions regarding stewardship of organizational resources. As a physician, Dr. Smith has a
primary duty to patient wellbeing. However, his financial interests are clearly impacted by the
success of his private clinic. This divided loyalty compounds concerns about the unconventional
treatments he champions potentially being driven by self-serving motivations rather than sound
evidence. There are also rumors that Dr. Smith is struggling financially due to an expensive
divorce settlement. This raises the possibility of fraudulent practices being employed to generate
funds needed to meet legal obligations. For instance, prescribing non-approved medicines creates
opportunities to exploit desperate patients by offering false hope and charging for unproven
treatments (Borysowski et al., 2019). Even if fraud is not occurring, the perception or possibility
of misplaced motives damages public trust in our hospital, and conflict policies requiring
disclosure of Dr. Smith’s financial stressors have likely been violated.
Addressing the Problems
As the director of pharmacy, I have a responsibility to report these regulated safety
concerns through appropriate channels as required by policy and ethical codes of conduct. The
medication-related issues fall under my scope of practice. I will arrange an urgent meeting with
5
the chief medical officer and chief compliance officer to disclose the details of this case and
discuss options to launch an investigation. I will disclose the specifics of the issues discovered,
the parties involved, and the evidence and sources that I have gathered. I will emphasize the
threats this situation poses to patient safety, quality of care, hospital reputation, community trust,
and ethical standards.
As leaders of our institution, we must model principled decision-making even when
facing difficult situations that involve respected physicians. Our hospital has a duty to thoroughly
investigate questionable practices, restrict privileges as warranted to protect patients, and report
substantiated misconduct to regulatory bodies. It is prudent to place Dr. Smith on administrative
leave pending investigation, given the severity of the concerns. Appropriate disciplinary action
and external reporting should follow if claims are founded (Bell & Richards, 2021). Extensive
audits of documentation informed consent procedures, Cancer Committee reviews, and payer
billing records for Dr. Smith’s patients will help determine the extent of deviations from the
standard of care. Identified at-risk patients should also be informed of the complaints against Dr.
Smith and offered assistance with transitioning care to another oncologist.
If investigation findings do not conclusively confirm misconduct, the executive team
should require Dr. Smith to undergo additional training on ethics, prescribing regulations,
conflict of interest policies, standardized treatment protocols, evidence-based medicine, peer
review procedures, and documentation. More rigorous oversight measures should be enacted,
such as requiring the Cancer Committee’s approval for off-label prescribing or the use of nonformulary agents (Bell & Richards, 2021). Compliance audits should be repeated periodically,
and feedback should be shared transparently with Dr. Smith to support improvement.
6
However, if credible evidence clearly demonstrates exploitation, fraud, or patient endangerment,
termination would be warranted. The board of directors would need to review the results given
Dr. Smith’s high profile. A communications plan should be enacted across departments to
maintain morale and convey the hospital’s commitment to accountability and ethical practice
standards (Van Norman, 2023). Regulatory bodies would also need to be contacted per
mandatory reporting obligations. With thoughtful inquiry, proper policies, and ethical courage,
our leadership can maintain integrity even when facing difficult decisions involving well-known
physicians. Our duty is to honor ethical codes and model principled practices.
Christian Worldview
As followers of Christ, we are called to act with justice, mercy, and faithfulness
(Matthew 23:23). My responsibility as a director of pharmacy is to honor godly virtues and
biblical principles as I address concerning behaviors by a physician at my institution. I must seek
truth and confront injustice while also offering grace. The ethical issues presented in this case
grieved my spirit, as deception and exploitation violate fundamental Christian beliefs. However,
my duty is to approach this complex situation with humility, wisdom, and discernment to
uncover truth yet also allow for redemption where possible (Proverbs 2:6, Galatians 6:1). As in
the parable of the lost sheep (Luke 15:3-7), it is right to seek that which was astray to gently
restore things to order.
As Christian leaders, we know that all fall short of righteousness (Romans 3:23). So,
while consequences for harmful actions may be warranted, our aim should also be to rebuild and
reconcile through open and honest dialogue (Proverbs 10:18, Matthew 5:23-24). As the apostle
Paul wrote, “The fruits of the spirit are love, joy, peace, patience, kindness, goodness,
faithfulness, gentleness and self-control” (Galatians 5:22-23). These virtues can guide difficult
7
discussions about concerning behaviors to promote confession, changed hearts, and restoration
of trust. Scripture compels us to make just decisions but also to season justice with grace. As the
book of Zechariah states, “Administer true justice; show mercy and compassion to one another”
(Zechariah 7:9). The holy calling on Christian hospitals is to nurture right living in a spirit of
generosity, not merely enforce rigid rules. Our health systems must model Christ-centered care.
This challenging circumstance provides an opportunity for our hospital’s leadership to
demonstrate love and redemptive action. Jesus sets the standard as both righteous judge and
sacrificial lamb (John 8:7, Revelation 5:6). May we mirror such ethically courageous
compassion.
Conclusion
The concerning medication prescribing patterns by Dr. Smith present an ethical dilemma
as the director of pharmacy. However, by gathering clear details regarding the issues and
reporting through proper channels, a fair yet thorough investigation can be conducted. Our
hospital must prioritize patient safety, quality standards, and community trust. Appropriate
disciplinary measures should follow if policy violations are substantiated. Yet this difficult
circumstance also provides an opportunity to demonstrate Christian virtues. Scripture calls us to
act with justice, mercy, and faithfulness. So, while consequences for harmful actions may be
warranted, our aim should also be to rebuild and reconcile through open and honest dialogue. As
Christian leaders, we know that all fall short. My prayer is that this process will lead to
confession, changed hearts, and restoration of trust by God’s grace.
8
References
Bell, J. S., & Richards, G. C. (2021). Off-label medicine use: Ethics, practice, and future
directions. Australian Journal of General Practice, 50(5), 329–
331. https://doi.org/10.31128/ajgp-08-20-5591
Borysowski, J., Ehni, H., & Górski, A. (2019). Ethics codes and use of new and innovative
drugs. British Journal of Clinical Pharmacology, 85(3), 501–
507. https://doi.org/10.1111/bcp.13833
Lee, S., Yang, M. H., Kim, J. S., Cho, Y., Choi, N., Cho, E. J., Park, J. D., Choi, Y. H., & Choi,
K. H. (2023). Evaluation of off-label medication use and drug safety in a pediatric
intensive care unit. Saudi Pharmaceutical Journal, 31(9),
101704. https://doi.org/10.1016/j.jsps.2023.101704
The Holy Bible, a new international version. (1984). Grand Rapids: Zondervan Publishing
House.
Van Norman, G. A. (2023). Off-label use vs off-label marketing of drugs. JACC: Basic to
Translational Science, 8(2), 224–233. https://doi.org/10.1016/j.jacbts.2022.12.011